Convergence Investment Partners’s Sucampo Pharmaceuticals, Inc. SCMP Stock Holding History

Convergence Investment Partners’s Portfolio SCMP Stock Details SCMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-57,700	Closed	-$631K	–	407
2016 Q1	$631K	Sell	57,700 -43,150	-43%	-$545K	0.08%	288
2015 Q4	$1.74M	Buy	100,850 +30,260	+43%	+$543K	0.2%	182
2015 Q3	$1.4M	Sell	70,590 -59,980	-46%	-$1.38M	0.16%	209
2015 Q2	$2.15M	Buy	130,570 +2,440	+2%	+$42.3K	0.21%	161
2015 Q1	$1.99M	Buy	128,130 +60,380	+89%	+$936K	0.28%	132
2014 Q4	$967K	Buy	+67,750	New	+$716K	0.13%	253

Other funds holding SCMP

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Teachers Advisors New York $81.7B AUM 13.62% 1-Year Est. Return

Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return

Convergence Investment Partners's SCMP Position: Q2 2016 in Review

Convergence Investment Partners sold out of Sucampo Pharmaceuticals, Inc. (SCMP) in Q2 2016, closing a stake of 57,700 shares — an estimated $631K sold.

Convergence Investment Partners first reported a position in SCMP in Q4 2014 and held it in 6 quarters. The position peaked at $2.15M in Q2 2015. 136 funds tracked by Wall St. Rank hold SCMP as of Q2 2016.

Convergence Investment Partners reported no remaining Sucampo Pharmaceuticals, Inc. position as of Q2 2016 after selling out during the quarter.
Convergence Investment Partners sold 57,700 Sucampo Pharmaceuticals, Inc. shares in Q2 2016, an estimated $631K.
Convergence Investment Partners first reported a position in Sucampo Pharmaceuticals, Inc. in Q4 2014 and held it in 6 quarters.
Convergence Investment Partners's Sucampo Pharmaceuticals, Inc. position peaked at $2.15M in Q2 2015.
136 funds tracked by Wall St. Rank held Sucampo Pharmaceuticals, Inc. as of Q2 2016.

Based on Convergence Investment Partners's 13F filing for Q2 2016, filed 10 Aug 2016.